Key statistics dashboard for Immuneering Corporation (IMRX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations.
Stock Data
| Price | $4.45 |
| Market Cap | $162M |
| Beta | 0.43 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -4.30 |
| Price / Book | 1.52 |
| P/S | 0.00 |
| P/FCF | -2.85 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 19.47 |
| Quick Ratio | 19.47 |
| Cash Ratio | 5.09 |
| Debt / Equity | 0.02 |
| Debt / Assets | 1.80% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 11.19 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.95 |
| Cash per share | 2.32 |
| FCF per share | -0.88 |
| Tangible Book Value per share | 2.84 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 4 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 11 |
| Avg rating (1-5) | 0.64 |
Related companies: ARCT · ASMB · ENTA · FHTX · HUMA · NAUT · PYXS
Explore sector: Healthcare · Biotechnology
More sections of IMRX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks